



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Medical benefit drug policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and therefore subject to change.

Effective Date: 02/08/2024

H.P. Acthar® Gel (repository corticotropin)

HCPCS: J0801

Policy:

Requests must be supported by submission of chart notes and patient specific documentation.

- A. Coverage of the requested drug is provided when all the following are met:
 - a. Diagnosis of West Syndrome (infantile spasms) in infants and children under 2 years of age
 - b. Trial and failure, contraindication, OR intolerance to the preferred drugs as listed in BCBSM/BCN's utilization management medical drug list and/or BCBSM/BCN's prior authorization and step therapy documents
- B. Quantity Limitations, Authorization Period and Renewal Criteria
 - a. Quantity Limits: 4 vials per 30 days
 - b. Authorization Period: 60 days
 - c. Renewal Criteria: Not applicable as no further authorization will be provided

***Note: Coverage and approval duration may differ for Medicare Part B members based on any applicable criteria outlined in Local Coverage Determinations (LCD) or National Coverage Determinations (NCD) as determined by Center for Medicare and Medicaid Services (CMS). See the CMS website at <http://www.cms.hhs.gov/>. Determination of coverage of Part B drugs is based on medically accepted indications which have supported citations included or approved for inclusion determined by CMS approved compendia.

Background Information:

- Repository corticotropin injection is adrenocorticotrophic hormone (ACTH) from a bovine or porcine source which stimulates the adrenal cortex to produce cortisol, corticosterone, and a number of other hormones. Repository corticotropin was first approved for sale in the United States in 1952. It has been used in a number of different indications, however commercial availability of corticosteroids (e.g. hydrocortisone, prednisone, methylprednisolone), all available as much lower-cost generics have come into favor.
- H.P. Acthar is indicated for a variety of inflammatory conditions including:
 - Infantile spasms: Repository corticotropin injection is indicated as monotherapy for the treatment of infantile spasms in patients under 2 years of age.

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.

- Multiple Sclerosis: Repository corticotropin injection is indicated for the treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown repository corticotropin to be effective in speeding the resolution of acute exacerbations of multiple sclerosis.
 - However, there is no evidence that it affects the ultimate outcome or natural history of the disease.
- Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis, Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), Ankylosing spondylitis.
- Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus, systemic dermatomyositis (polymyositis).
- Dermatologic Diseases: Severe erythema multiforme, Stevens-Johnson syndrome.
- Allergic States: Serum sickness.
- Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation.
- Respiratory Diseases: Symptomatic sarcoidosis.
- Edematous State: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.
- The intent of this policy is to cover repository corticotropin for infantile spasms, which in 2010 has shown sufficient evidence of effectiveness, based on cessation of spasms, and amelioration of electroencephalogram (EEG); however, it is not efficacious in the prevention of other seizure types, improvement of long term developmental outcomes, or any other outcomes. Additional indications are grandfathered given trials establishing efficacy were not required when originally approved.
- The 2010 U.S. consensus report on infantile spasms recommends initiating a taper of ACTH after two weeks of therapy at the maximum dose. Relapses are not uncommon in those who respond to initial therapy and in one study 5 of 24 patients relapsed within 12-33 months. A second course of the therapy can be administered.
- According to Micromedex, "In much of the literature, it is unclear whether natural ACTH or cosyntropin was administered for a large variety of indications
 - Diagnosis of corticotropin insufficiency, acute gout, Guillain-Barre' syndrome, control of infantile spasms, and childhood seizures, Bell's palsy, multiple sclerosis, rheumatic diseases, vitiligo, myasthenia gravis, herpes zoster, asthma and status asthmaticus, ulcerative colitis, diagnosis of Sheehan's syndrome, adjunct to smoking cessation, schizophrenia, hay fever, myoclonic encephalopathy, acute inflammatory polyneuropathy, and prevention of peripheral neuropathy, nausea, and vomiting during cisplatin chemotherapy
- There is insufficient evidence to establish efficacy for the additional indications and there is no evidence of superiority compared to cost effective alternatives (i.e. generic corticosteroids). A literature search did not identify published articles that evaluated the use of ACTH gel compared to use of corticosteroids in corticosteroid-responsive conditions. Use of ACTH gel has the potential to cause more adverse effects. Thus, given this lack of comparative data and the statement in the product information-labeling, the clinical need (and clinical impact) to use ACTH gel for

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.

steroid-responsive conditions has not been demonstrated. Thus, use of ACTH gel in this clinical situation is not covered.

References:

1. 2011 RegenceRx- Therapeutic Class ReviewSM- Anticonvulsants: Focus on ezogabine (Potiga™) and corticotrophin gel (H.P. Acthar®).
2. Micromedex Healthcare Series [internet database]. Updated periodically. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc. May 2011.
3. Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev. 2008(4):CD001770.
4. Hrachovy RA, Frost JD, Jr., Glaze DG. High-dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms. J Pediatr. 1994 May;124(5 Pt 1):803-6.
5. Hrachovy RA, Frost JD, Jr., Kellaway P, Zion TE. Double-blind study of ACTH vs prednisone therapy in infantile spasms. J Pediatr. 1983 Oct;103(4):641-5.
6. Baram TZ, Mitchell WG, Tournay A, Snead OC, Hanson RA, Horton EJ. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics. 1996 Mar;97(3):375-9.
7. Mackay MT, Weiss SK, Adams-Webber T, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology. 2004 May 25;62(10):1668-81.
8. Pellock JM, Hrachovy R, Shinnar S, et al. Infantile spasms: a U.S. consensus report. Epilepsia. Oct;51(10):2175-89.
9. H.P. Acthar Gel (repository corticotropin injection) [prescribing information]. Hazelwood, MO: Mallinckrodt; October 2021.
10. Glaze DG. Management and prognosis of infantile spasms. UpToDate. <https://www.uptodate.com/contents/management-and-prognosis-of-infantile-spasms> [accessed June 9th, 2020].

Policy History												
#	Date	Change Description										
2.3	Effective Date: 02/08/2024	Annual review of medical policy. No changes to the criteria were made at this time										
2.2	Effective Date: 04/06/2023	Updated the approval duration to allow for 60 day requirement										
2.1	Effective Date: 08/04/2022	Annual review of criteria was performed, no changes were made										
2.0	Effective Date: 08/12/2021	Annual Review of Medical Policy										
1.9	Effective Date: 08/13/2020	Annual Review of Medical Policy										
1.8	Effective Date: 08/15/2019	Annual Review of Medical Policy										
1.7	Effective Date: 08/09/2018	Annual Review of Medical Policy										
1.6	Effective Date: 08/10/2017	Annual Review of Medical Policy										
1.5	Effective Date: 08/11/2016	Annual Review of Medical Policy										
1.4	Effective Date: 01/22/2013	UM medical management system update for BCBS and BCN <table border="1" data-bbox="500 915 1380 1123"> <thead> <tr> <th>Line of Business</th> <th>PA Required in Medical Management System (Yes/No)</th> </tr> </thead> <tbody> <tr> <td>BCBS</td> <td>Yes</td> </tr> <tr> <td>BCN</td> <td>Yes</td> </tr> <tr> <td>MAPPO</td> <td>No</td> </tr> <tr> <td>BCNA</td> <td>No</td> </tr> </tbody> </table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	Yes	BCN	Yes	MAPPO	No	BCNA	No
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	Yes											
BCN	Yes											
MAPPO	No											
BCNA	No											
1.3	Effective Date: 12/17/2012	Criteria Updates										
1.2	Effective Date: 08/09/2012	Criteria Updates										
1.1	Effective Date: 09/01/2009	Criteria Updates										
1.0	Effective Date: 01/29/2009	New Criteria <table border="1" data-bbox="500 1413 1380 1621"> <thead> <tr> <th>Line of Business</th> <th>PA Required in Medical Management System (Yes/No)</th> </tr> </thead> <tbody> <tr> <td>BCBS</td> <td>No</td> </tr> <tr> <td>BCN</td> <td>No</td> </tr> <tr> <td>MAPPO</td> <td>No</td> </tr> <tr> <td>BCNA</td> <td>No</td> </tr> </tbody> </table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	No	BCN	No	MAPPO	No	BCNA	No
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	No											
BCN	No											
MAPPO	No											
BCNA	No											

* The prescribing information for a drug is subject to change. To ensure you are reading the most current information it is advised that you reference the most updated prescribing information by visiting the drug or manufacturer website or <http://dailymed.nlm.nih.gov/dailymed/index.cfm>.

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.

Blue Cross Blue Shield/Blue Care Network of Michigan
Medication Authorization Request Form
HP ACTHAR GEL® (repository corticotropin) HCPCS CODE: J0801



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for HP ACTHAR GEL®. For commercial members only, please complete this form and submit via fax to 877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION	PHYSICIAN INFORMATION
Name	Name
ID Number	Specialty
D.O.B. <input type="checkbox"/> Male <input type="checkbox"/> Female	Address
Diagnosis	City /State/Zip
Drug Name	Phone/Fax: P: () - F: () -
Dose and Quantity	NPI
Directions	Contact Person
Date of Service(s)	Contact Person Phone / Ext.

STEP 1: DISEASE STATE INFORMATION

- Initiation or Continuation of treatment? Initiation Continuation *Date patient started therapy:* _____
- How is this medication being administered? Self-administered (***Please fax this completed form to BCBSM at (866) 601-4425***)
 Health Care Professional administered
- Please provide the NPI number for the place of administration: _____
- Initiation AND Continuation of Therapy:**
 - Please check the patient's diagnosis:
 Infantile spasms
 Other: _____
- Continuation of therapy:
 - Please provide rationale for continuation: _____

Please add any other supporting medical information necessary for our review

Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.

Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

Physician's Name	Physician Signature	Date
Step 2 Checklist <input type="checkbox"/> Form Completely Filled Out <input type="checkbox"/> Attached Chart Notes	<input type="checkbox"/> Corticosteroids Responsiveness <input type="checkbox"/> Supporting literature as necessary	
Step 3 Submit	By Fax: BCBSM Specialty Pharmacy Mailbox 1-877- 325-5979	By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320

Confidentiality notice: This transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of this document is strictly prohibited. If you have received this in error, please notify the sender to arrange for the return of this document.